The Inhibition of Extended Spectrum β-Lactamases: Hits and Leads

Title:The Inhibition of Extended Spectrum β-Lactamases: Hits and Leads

Volume: 21 Issue: 12

Author(s): Davide Farina, Francesca Spyrakis, Alberto Venturelli, Simon Cross, Donatella Tondi and Maria Paola Costi

Affiliation:

Keywords: β-lactam antibiotics, β-lactamase binding site, β-lactamase inhibitors, carbapenemase, extended spectrum β- lactamases, molecular interaction fields, resistance.

Abstract: The ongoing emergence of bacterial strains resistant to even third- and fourth-generation β-lactam antibiotics is one of the most pressing and challenging issues in clinical therapy. Furthermore, under the pressure of antibiotics used ubiquitously over the last 80 years, functional mutations and new resistances are continuously increasing. Therefore, new drugs and new approaches to the infections produced by multidrug-resistant Gram-negative bacteria are categorically necessary and expected by the scientific community. This review describes the most deleterious known extended-spectrum β- lactamases and the molecules now available for targeting bacterial infections. The active-site chemical and geometric properties that are potentially exploitable for the design of both broad-spectrum and selective compounds are described.

Cite this article as:

Farina Davide, Spyrakis Francesca, Venturelli Alberto, Cross Simon, Tondi Donatella and Costi Paola Maria, The Inhibition of Extended Spectrum β-Lactamases: Hits and Leads, Current Medicinal Chemistry 2014; 21 (12) . https://dx.doi.org/10.2174/09298673113206660323